Reber Genetics Co (瑞寶公司), which makes vaccines for pigs, yesterday said it would expand sales of its drug to Asian countries by the end of this year, which would offset a decline in sales in the local market due to an outbreak of acute porcine diarrhea.
From January through March, acute diarrhea killed 10 percent of the nation’s pigs, resulting in fewer pigs being vaccinated this year to prevent porcine reproductive and respiratory syndrome (PRRS), Reber Genetics Co chief operating officer Shelley Chiou (邱麗真) told an investors’ conference yesterday.
The vaccine is currently Reber’s only product, while it is developing other vaccines for the prevention of porcine circovirus type 2, foot-and-mouth disease and acute diarrhea, according to the company.
The company reported a 16.8 percent decline in revenue to NT$18.65 million (US$611,900) in the first nine months of this year, compared with NT$22.42 million a year ago, according to a filing with the Taiwan Stock Exchange.
However, Reber does not expect revenue to slide on an annual basis this year, because it has received a drug permit in August to sell its PRRS vaccine in Russia, and the drug is expected to be approved in the Philippines and Vietnam by the end of this year, Chiou said.
The company launched the vaccine locally in April 2012 and shipped a total of 860,000 vials domestically that year, the same as its largest competitor, Chiou said, adding that shipments of the drug rose twofold last year to 1.8 million vials.
Reber Genetics Co director Albert Hung (洪岳鵬) said the nation’s accessible pig vaccine market is about 6.14 million pigs, while the market is 21.4 million pigs in Russia, 7.98 million pigs in Vietnam and 8.55 million pigs in the Philippines.
Hung said the company would get more than 10 percent of the market share in Russia, because PRRS is prevalent there.
Although the company has only one product now, Hung said Reber aims to become one of the top companies producing animal vaccines within the next eight to 10 years.
“There is a company called Boehringer, which I never heard of when I completed my master’s degree, but now is the largest company in Asia because of two vaccines,” Hung said.
However, Reber registered losses of NT$68.68 million, or NT$1.11 per share, in the first half of this year and it will remain in the red throughout this year, he added.
The company will strive to make a profit next year as it expands into new markets, company chairman Chang Hsiu-kang (章修綱) said.
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday said that its investment plan in Arizona is going according to schedule, following a local media report claiming that the company is planning to break ground on its third wafer fab in the US in June. In a statement, TSMC said it does not comment on market speculation, but that its investments in Arizona are proceeding well. TSMC is investing more than US$65 billion in Arizona to build three advanced wafer fabs. The first one has started production using the 4-nanometer (nm) process, while the second one would start mass production using the
A TAIWAN DEAL: TSMC is in early talks to fully operate Intel’s US semiconductor factories in a deal first raised by Trump officials, but Intel’s interest is uncertain Broadcom Inc has had informal talks with its advisers about making a bid for Intel Corp’s chip-design and marketing business, the Wall Street Journal reported, citing people familiar with the matter. Nothing has been submitted to Intel and Broadcom could decide not to pursue a deal, according to the Journal. Bloomberg News earlier reported that Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) is in early talks for a controlling stake in Intel’s factories at the request of officials at US President Donald Trump’s administration, as the president looks to boost US manufacturing and maintain the country’s leadership in critical technologies. Trump officials raised the
‘SILVER LINING’: Although the news caused TSMC to fall on the local market, an analyst said that as tariffs are not set to go into effect until April, there is still time for negotiations US President Donald Trump on Tuesday said that he would likely impose tariffs on semiconductor, automobile and pharmaceutical imports of about 25 percent, with an announcement coming as soon as April 2 in a move that would represent a dramatic widening of the US leader’s trade war. “I probably will tell you that on April 2, but it’ll be in the neighborhood of 25 percent,” Trump told reporters at his Mar-a-Lago club when asked about his plan for auto tariffs. Asked about similar levies on pharmaceutical drugs and semiconductors, the president said that “it’ll be 25 percent and higher, and it’ll
CHIP BOOM: Revenue for the semiconductor industry is set to reach US$1 trillion by 2032, opening up opportunities for the chip pacakging and testing company, it said ASE Technology Holding Co (日月光投控), the world’s largest provider of outsourced semiconductor assembly and test (OSAT) services, yesterday launched a new advanced manufacturing facility in Penang, Malaysia, aiming to meet growing demand for emerging technologies such as generative artificial intelligence (AI) applications. The US$300 million facility is a critical step in expanding ASE’s global footprint, offering an alternative for customers from the US, Europe, Japan, South Korea and China to assemble and test chips outside of Taiwan amid efforts to diversify supply chains. The plant, the company’s fifth in Malaysia, is part of a strategic expansion plan that would more than triple
RSS